Active pharmaceutical ingredients (APIs) are produced in Syntagon’s state-of-the-art pilot plant with reactor capacities ranging from 20 to 800 liters. Clinical material is made under GMP (Good Manufacturing Process) in full compliance with ICH Q7 guidelines (link to ICH Q7a). Our pilot plant has five physically separated production suites, designed to operate under ISO 8 standards or better, that allow for simultaneous product campaigns.

For high-potency products, a dedicated facility equipped with state-of-the-art containment technology and air locks assures safe handling.
Read more about GMP manufacturing of high potency compounds.